Resources for Publication: Phenotypic reversion and target prioritization for cellular inflammation via representation learning with foundation models

Read full text
Authors: Daniel Wong
Cited by: 0

Abstract

Dataset resources for the publication: "Phenotypic reversion and target prioritization for cellular inflammation via representation learning with foundation models." see GithHub: https://github.com/pfizer-opensource/phenotype_reversion imru_full.h5ad contains the transcript count matrix. the 'gene_target' column reflects the gene that was knocked down via CRISPRi, while the 'condition' column refers to whether or not the cells were treated with IL-1B & TNFa If the cytokine was introduced the treatment condition = 'Treated' else 'Untreated'. The controls in the 'gene_target' column are denoted as no target ('NO-TARGET') or safe target ('SAFE_TARGET'). .obs contains keys: ['condition', 'cellID', 'cell_treat', 'n_genes', 'nGene', 'nUMI', 'log10GenesPerUMI', 'mitoRatio', 'gene_target', 'guide', 'welltag', 'flask'] both treated and untreated condition have same controls, and roughly same sets of perturbations except: treated has unique perturbations: ['SH3PXD2A', 'EMCN', 'RAB11FIP3', 'CKAP5', 'POLR2K'] untreated has unique perturbations: ['VWF', 'HNRNPA3', 'TRIM13', 'CORO1C', 'DDX27', 'PACSIN2'] For all .h5ad files, adata.X will contain the embedding as np array, adata.obsm['umap'] will contain the coordinates of UMAP applied to the embedding, e.g. adata.obsm['umap'] = UMAP(adata.X) For convenience, the single cell embeddings as well as UMAP reductions of those embeddings for the different single cell foundation models have also been provided in this data repository. Place all the files in this repository in your local project directory: phenotype_reversion/data/.

Fields of Study & Subjects

Single-cell and spatial transcriptomics Computational Drug Discovery Methods CRISPR and Genetic Engineering

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
4 March 2026
Language
EN